INBX Stock — Inhibrx Biosciences Inc.: Cash, EV, Pipeline

Share price

$109.35

Market cap

$1,609.4M

Cash

$133.3M

Enterprise value

$1,652.3M

Balance sheet

Cash	$133.3M
Debt	$176.3M
Net cash	-$42.9M
Enterprise value	$1,652.3M
Basic shares	14.7M shares
Fully diluted shares	19.6M shares
Fully diluted market cap	$2,147.6M
Cash per share	$9.07

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading INBX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	INBRX-109	Phase 1	Ewing Sarcoma; Colorectal Adenocarcinoma	—
Jun 12 - Jul 24	INBRX-106	Phase 3	Head and Neck Squamous Cell Carcinoma (HNSCC)	—
Aug 12 - Sep 23	INBRX-106 - Hexavalent OX40 agonist antibody	Phase 2	Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Ozekibart

Phase 3 · Active

Aliases INBRX-109

Target DR5

Indications

Conventional chondrosarcoma (Phase 3)
Colorectal cancer (Phase 1)
Ewing sarcoma (Phase 1)

Catalysts

— first quarter of 2027
— 2027

Status note Tetravalent DR5 agonist. Randomized chondrosarcoma trial completed (Oct 2025); FDA accepted BLA for filing in conventional chondrosarcoma (Jun 2026). Two new CRC Phase 1 cohorts initiated Q2 2026. FDA meeting planned Q4 2026 to discuss 1L registration path.

INBRX-106

Phase 2 · Active

Target OX40

Indications

Head and neck squamous cell carcinoma (Phase 2)
Non-small cell lung cancer (Phase 2)

Status note Hexavalent OX40 agonist. Randomized 1L Phase 2 portion of HexAgon study (with pembrolizumab) in PD-L1+ metastatic/unresectable recurrent HNSCC reported interim results May 2026; also being investigated in NSCLC.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	INBRX-106
Lead indication	Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead phase	Phase 3
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06295731	Phase 3	Active, not recruiting	Sponsor	INBX	—	Head and Neck Squamous Cell Carcinoma (HNSCC)	—
NCT04198766	Phase 2	Recruiting	Sponsor	INBX	MRK	Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer	—
NCT04950075	Phase 2	Active, not recruiting	Sponsor	INBX	—	Conventional Chondrosarcoma	—
NCT03715933	Phase 1	Recruiting	Sponsor	INBX	—	Ewing Sarcoma; Colorectal Adenocarcinoma	—
NCT06353997	Phase 2	Recruiting	Collaborator	Providence Health & Services	—	Triple Negative Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Inhibrx Biosciences, Inc on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

INBX — Inhibrx Biosciences Inc.